GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Loans Receivable

I-MAB (IMAB) Loans Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Loans Receivable?

I-MAB's Loans Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

I-MAB Loans Receivable Historical Data

The historical data trend for I-MAB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Loans Receivable Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

I-MAB Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

I-MAB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

I-MAB Loans Receivable Related Terms

Thank you for viewing the detailed overview of I-MAB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Loans Receivable
Comparable Companies
ACET DOMH EPIX NTRB CRBP ACRV JSPR MNOV VANI ABOS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0VY:Germany
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
Website
https://www.i-mabbiopharma.com
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).